The ophthalmic treatment developer has now raised almost $36m in total, with CR-CP Life Science Fund having led a $25m round.
CR-CP Life Science Fund, formed by conglomerates China Resources Group and Charoen Pokphand Group, co-led a $25m series C round for Israel-based ophthalmic implant developer EyeYon Medical yesterday.
The round was co-led by an unnamed strategic leader in the ophthalmic industry and it also featured GHS Fund, BPC, Triventures, Rimonci Capital, Pontifax and Diamond BioFund.
EyeYon’s products include EndoArt, a synthetic implant designed to treat chronic corneal oedema, and Hyper CL, a contact lens treatment for a variety of corneal…
